MX421186B - Constructos de anticuerpos. - Google Patents

Constructos de anticuerpos.

Info

Publication number
MX421186B
MX421186B MX2019004690A MX2019004690A MX421186B MX 421186 B MX421186 B MX 421186B MX 2019004690 A MX2019004690 A MX 2019004690A MX 2019004690 A MX2019004690 A MX 2019004690A MX 421186 B MX421186 B MX 421186B
Authority
MX
Mexico
Prior art keywords
antibody constructs
constructs
presented
methods
pharmaceutical compositions
Prior art date
Application number
MX2019004690A
Other languages
English (en)
Spanish (es)
Other versions
MX2019004690A (es
Inventor
Bryan Glaser
Lucas Bailey
Qufei Li
Roland Green
Original Assignee
Invenra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invenra Inc filed Critical Invenra Inc
Publication of MX2019004690A publication Critical patent/MX2019004690A/es
Publication of MX421186B publication Critical patent/MX421186B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2019004690A 2016-10-19 2017-10-18 Constructos de anticuerpos. MX421186B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662410054P 2016-10-19 2016-10-19
US201762549894P 2017-08-24 2017-08-24
US201762555498P 2017-09-07 2017-09-07
PCT/US2017/057268 WO2018075692A2 (en) 2016-10-19 2017-10-18 Antibody constructs

Publications (2)

Publication Number Publication Date
MX2019004690A MX2019004690A (es) 2019-09-27
MX421186B true MX421186B (es) 2025-02-10

Family

ID=60452719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004690A MX421186B (es) 2016-10-19 2017-10-18 Constructos de anticuerpos.

Country Status (10)

Country Link
US (2) US20180118811A1 (enExample)
EP (1) EP3529269B1 (enExample)
JP (2) JP7261158B2 (enExample)
KR (3) KR20240000650A (enExample)
CN (3) CN118359705A (enExample)
AU (1) AU2017345454B2 (enExample)
CA (1) CA3041254A1 (enExample)
IL (1) IL266143A (enExample)
MX (1) MX421186B (enExample)
WO (1) WO2018075692A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211273T1 (hr) 2014-11-26 2021-11-12 Xencor, Inc. Heterodimerna protutijela koja vežu cd3 i cd20
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
FI3468586T3 (fi) 2016-06-14 2024-10-29 Xencor Inc Bispesifisiä immuuniaktivaatiota vapauttavia vasta-aineita
CA3041254A1 (en) * 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
US20210163594A1 (en) * 2018-04-17 2021-06-03 Invenra Inc. Binding molecules
MX2020010881A (es) 2018-04-18 2020-11-09 Exelixis Inc Construcciones de anticuerpos anti-ror.
JP7193628B2 (ja) * 2018-07-06 2022-12-20 北京天成新脉生物技▲術▼有限公司 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用
EP3830129A4 (en) * 2018-07-30 2022-05-04 Invenra, Inc. MULTISPECIFIC TREG-BINDING MOLECULES
BR112021006784A2 (pt) * 2018-10-10 2021-09-21 Zymeworks Inc. Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos
BR112021012338A2 (pt) 2018-12-24 2021-09-14 Sanofi Proteínas de ligação multiespecíficas com domínios fab mutantes
EP4077374A4 (en) * 2019-12-20 2023-12-27 Kisoji Biotechnology Inc. POLYPEPTIDES, PROTEIN COMPLEXES AND ASSOCIATED PRODUCTION PROCESS
CA3168444A1 (en) * 2020-02-20 2021-08-26 Win Therapeutics, Inc. Bispecific gd2 and b7h2 binding molecules and methods of use
US12312418B2 (en) * 2020-12-10 2025-05-27 Invenra Inc. Orthogonal mutations for heterodimerization
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
TW202506726A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 雙特異性工程化抗體
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905551D0 (en) * 1989-03-10 1989-04-19 Unilever Plc Detergent compositions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
EP2217283A2 (en) 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
KR20150080038A (ko) 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
CL2009002167A1 (es) 2008-12-10 2010-10-15 Mersana Therapeutics Inc Formulacion farmaceutica para administracion endovenosa que comprende un compuesto derivado de conjugados de camptotecina-polimero biocompatibles y biodegradables, un agente de estabilizacion, uno o varios tampones y un tensoactivo, util para el tratamiento del cancer.
CA2762877A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
RS58810B1 (sr) 2009-06-03 2019-07-31 Immunogen Inc Metodi konjugacije
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
RU2620071C2 (ru) * 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
SG193022A1 (en) 2011-03-10 2013-10-30 Eisai R&D Man Co Ltd Method for screening for compound capable of enhancing or inhibiting oatp1b1 transport activity, and method for determining expression level of oatp1b1
EP2717916B1 (en) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
PL2794905T3 (pl) 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
CN120383672A (zh) * 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
MX2015004668A (es) 2012-10-25 2015-07-23 Medimmune Llc Formulacion estable de anticuerpos de baja viscosidad.
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
US20160022829A1 (en) 2013-03-14 2016-01-28 Mersana Therapeutics, Inc. Tubulysin compounds and conjugates thereof
EA032231B1 (ru) 2013-10-11 2019-04-30 Мерсана Терапьютикс, Инк. Конъюгаты белок-полимер-лекарственное средство
NZ758050A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US11116847B2 (en) 2013-12-19 2021-09-14 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
IL309933A (en) 2014-02-17 2024-03-01 Seagen Inc Hydrophilic antibody-drug conjugates
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
CA2942150A1 (en) 2014-04-07 2015-10-15 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
US9808528B2 (en) 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI551060B (zh) * 2014-09-24 2016-09-21 衡宇科技股份有限公司 Ｂｃｈ解碼方法及其解碼器
JP6904902B2 (ja) * 2014-12-05 2021-07-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ドメイン交換抗体
WO2016180941A1 (en) 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
EP3653628B1 (en) 2015-07-21 2022-09-14 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
EP3411077A1 (en) 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
EP3241531A1 (en) * 2016-05-04 2017-11-08 noonee AG Leg unit for a wearable sitting posture assisting device
CA3041254A1 (en) * 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
WO2019204398A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Trivalent trispecific antibody constructs
US20210163594A1 (en) * 2018-04-17 2021-06-03 Invenra Inc. Binding molecules
MX2020010881A (es) * 2018-04-18 2020-11-09 Exelixis Inc Construcciones de anticuerpos anti-ror.
EP3830129A4 (en) * 2018-07-30 2022-05-04 Invenra, Inc. MULTISPECIFIC TREG-BINDING MOLECULES
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules

Also Published As

Publication number Publication date
US20240043502A1 (en) 2024-02-08
MX2019004690A (es) 2019-09-27
CA3041254A1 (en) 2018-04-26
AU2017345454A1 (en) 2019-05-30
JP2022176374A (ja) 2022-11-25
KR102617264B1 (ko) 2023-12-29
IL266143A (en) 2019-06-30
US20180118811A1 (en) 2018-05-03
WO2018075692A3 (en) 2019-04-04
EP3529269B1 (en) 2025-11-26
JP7261158B2 (ja) 2023-04-19
KR20240000650A (ko) 2024-01-02
CN118359704A (zh) 2024-07-19
CN118359705A (zh) 2024-07-19
CN110177805A (zh) 2019-08-27
JP7591015B2 (ja) 2024-11-27
KR20190092380A (ko) 2019-08-07
WO2018075692A2 (en) 2018-04-26
CN110177805B (zh) 2024-04-02
JP2019534277A (ja) 2019-11-28
EP3529269A2 (en) 2019-08-28
AU2017345454B2 (en) 2024-10-31
NZ752832A (en) 2025-06-27
KR20250044934A (ko) 2025-04-01

Similar Documents

Publication Publication Date Title
MX421186B (es) Constructos de anticuerpos.
PH12020551716A1 (en) Anti-ror antibody constructs
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MX2019007020A (es) Anticuerpos il-11.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MX2019007021A (es) Anticuerpos il-11ra.
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
SG10201803042PA (en) Anti-tim-3 antibodies
MY191581A (en) Anti-pd-1 antibodies
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
HK1234311A1 (en) Novel anti-rnf43 antibodies and methods of use
HK1238261A1 (en) Novel anti-mfi2 antibodies and methods of use
NZ744340A (en) Anti-jagged1 antibodies and methods of use